Armein Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 16.00 Cr
as on 07-07-2024
- Paid Up Capital ₹ 15.34 Cr
as on 07-07-2024
- Company Age 8 Year, 2 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 72.27 Cr
as on 07-07-2024
- Revenue 151.46%
(FY 2022)
- Profit -5513.44%
(FY 2022)
- Ebitda -721.50%
(FY 2022)
- Net Worth -50.77%
(FY 2022)
- Total Assets 17.90%
(FY 2022)
About Armein Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 16.00 Cr and a paid-up capital of Rs 15.34 Cr.
The company currently has active open charges totaling ₹72.27 Cr.
Nishant Patel, Suresh Patel, and Piyush Patel serve as directors at the Company.
- CIN/LLPIN
U24290GJ2016PTC093603
- Company No.
093603
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
05 Sep 2016
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Anand, Gujarat, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Armein Pharmaceuticals?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Nishant Patel  | Director | 05-Sep-2016 | Current |
| Suresh Patel | Director | 05-Sep-2016 | Current |
| Piyush Patel | Director | 05-Sep-2016 | Current |
Financial Performance and Corporate Structure Insights of Armein Pharmaceuticals.
Armein Pharmaceuticals Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 151.46% increase. The company also saw a substantial fall in profitability, with a 5513.44% decrease in profit. The company's net worth observed a substantial decline by a decrease of 50.77%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Armein Pharmaceuticals?
In 2022, Armein Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 19 Jun 2019 | ₹39.63 Cr | Open |
Others Creation Date: 19 Jun 2019 | ₹32.64 Cr | Open |
How Many Employees Work at Armein Pharmaceuticals?
Armein Pharmaceuticals has a workforce of 23 employees as of Apr 07, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Armein Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Armein Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
